As of 2026, no peer-reviewed human RCT (Randomised Controlled Trial) has tested subcutaneous GHK-Cu administration [7][9]
In clinical trials, significant weight loss is typically seen at the 12-to-16-week mark
Patient profiles that may be appropriate candidates include: Patients for whom a commercial option is clinically unsuitable due to documented sensitivities, intolerances, or formulary limitations Patients requiring a non-standard dose or delivery format that is not available in commercial products Patients participating in a structured, provider-supervised weight management program where individualized compounding supports the care plan Contraindications and cautions to evaluate: Personal or family history of medullary thyroid carcinoma or MEN 2 syndrome these warrant careful clinical review before any GLP-1 class compound Pancreatitis history document evaluation and discuss risk-benefit with patients Pregnancy or breastfeeding compounded weight management formulations are not appropriate
For those who pair it with realistic expectations and consistent habits, reviews show that it can become a reliable part of their wellness routine, offering long-term benefits and a sense of hope for the future
Division of Upper GI and General Surgery, Department of Surgery, University of Southern California Introduction: Elective cholecystectomies were among procedures deferred during the pandemic as recommended by guidelines published by various surgical organizations
